11 April 2003 | News
The Pune-based Serum Institute of India (SII) is in the process of conducting phase III clinical trials for a Hepatitis B-DTP (Diptheria, Tetanus and Pertussis) combination vaccine. The SII medical director, Subodh Bharadwaj, said, "Research is going on but it is too soon to predict when the vaccine will be commercially available." The SII is the largest manufacturer of vaccines in the country and have seen growth in the Hepatitis B segment, with the share of its GeneVac B recombinant vaccine growing at about 37 percent during 2002 with sales of Rs 10.28 crore.
Icrisat to set up agri-biotech park in AP
The International Crops Research Institute for Semi-Arid Tropics (ICRISAT) is
planning to set up an agri-biotech park as part of the Andhra Pradesh government's
Genome Valley project. A memorandum of understanding is expected to be signed
shortly with the state government. It has also taken steps to set up an agri-business
incubator with the state participation. An international biotechnology
colloquium, hoisted by the ICRISAT, has brought together stakeholders from the
global to the local level from international and national research institutes,
farmers' organizations, private sector, civil society to discuss ways to use
cutting-edge technology for removing poverty. It also raised voices of concern
on the transgenic crops and the need to put them through greater rigor on the
field before large-scale use.
Maximus2 launches ProjectX
Maximus2 is launching a project lifecycle solution called ProjectX that
offers a radically new way of managing people, processes and projects in a multi
project environment. According to Priti Unadkat, director, Maximus2, ProjectX is
completely browser based and enables any time anywhere access. It takes the pain
out of managing, administrating and executing multiple projects. Team members
can easily communicate and collaborate during project lifecycles. Unadkat said,
Strand Genomics is an early adopter of ProjectX.